A major strength of this study is that it represents only the second investigation of IL-6/GP130/JAK/STAT3 pathway activation in a substantial number of pancreatic cancer patient samples, following the recent work by Campos et al [9]. This evidence concerns the gene IL6 and familial pancreatic carcinoma.